

Press release

The Danish Council for Strategic Research supports 2cureX and its academic partners

Copenhagen, Denmark, 6 December 2010: 2cureX announced today that the Danish Council for Strategic Research has chosen to support the IndiTreat project with DKK 16,4 mill (EURO 2,2 mill). The aim of IndiTreat is to develop an easy to use technology that allows oncologists to tailor the combination therapy that is effective in the individual colorectal cancer patient. The project team comprises Bispebjerg Hospital, Rigshospitalet, DTU Nanotech, Århus University, Colorado Cancer Center (Denver, USA) and 2cureX.

“It is with excitement that we now with the support from the Danish Council for Strategic Research can launch the IndiTreat projects,” says Ole Thastrup, Chief Executive Officer of 2cureX. “The team behind IndiTreat possesses the scientific strength and innovative creativity needed to move the ChemoCellomics® technology, originally developed by 2cureX, to become a highly useful tool for the oncologists to tailor the effective treatment for the individual cancer patient”.

Colorectal cancer is among the most diagnosed cancers in the developed world with 279.220 and 148.810 annual incidences in EU and US, respectively. The swelling population combined with an unhealthy western lifestyle is expected to lead to a doubling of the diagnosed cancer cases in EU by 2020. Colorectal cancer patients experience a huge variation with regard to responsiveness to chemotherapy. There is therefore a tremendous unmet need to identify technologies that can identify the specific medical treatment that is effective in the individual patient.

About ChemoCellomics®

ChemoCellomics® integrates large drug libraries with cell functional screening and is originally developed to screen for new drugs in cells from patients. The proprietary technology allows namely, for the first time, high throughput cell-based screening directly in rare cells from patients. The aim of IndiTreat is to further develop this unique property to allow early identification of individualized in-vivo efficacious treatment regimens.

About 2cureX

The mission of 2cureX is

- Selection of individualized treatment regimen based on efficacy in cells from patients
- Drug discovery practicable at institutions with patient and disease knowledge

2cureX is private medtech company headquartered in Copenhagen, Denmark.

Contacts:

Ole Thastrup
Chief Executive Officer, 2cureX

Tel: +45 45822036
e-mail: ot@2curex.com

Timm Jessen
Chief Business Officer, 2cureX

Tel: +49 (4315) 606 448
e-mail: tj@2curex.com